Objective To examine rates of paediatric hospitalization for empyema and
Introduction
Streptococcus pneumoniae is the leading cause of bacterial infection in children worldwide and the most common cause of bacterial pneumonia in Australia, where it accounts for approximately one third of all cases. 1 In Australia, about 0.7% of all cases of pneumonia in children are complicated by empyema, which requires hospitalization for treatment and possible drainage. 2 S.pneumoniae is also the most common pathogen causing empyema. 3 The 7-valent pneumococcal conjugate vaccine (PCV7) was introduced in Australia's national immunization programme in two phases: in 2001 for indigenous and immunocompromised children less than 2 years of age, and in January 2005 for all children in this age group. In July 2011 the PCV7 was replaced by a 13-valent conjugate vaccine.
The PCV7 was administered as a three-dose series at ages 2, 4 and 6 months, without a booster.
Although pneumococcal conjugate vaccines have reduced invasive pneumococcal disease rates in children and adults throughout the world, [4] [5] [6] [7] [8] [9] several studies have reported a concomitant increase in empyema cases, both in the vaccinated and the non-vaccinated population. [10] [11] [12] [13] [14] [15] [16] [17] Because up to 90% of these cases have been caused by bacterial serotypes not included in the PCV7, [10] [11] [12] some fear that empyema may have emerged as a "replacement disease", i.e. disease produced by non-vaccine-related serotypes that have become predominant. Although we have reported the rates of childhood empyema in Australia elsewhere, 2 no previous studies have examined how the introduction of PCV7 has affected childhood empyema rates in this country. The objective of this study is to examine the incidence of paediatric hospitalizations for pneumonia and empyema in Australia before and after the introduction of the PCV7.
Methods
We reviewed the annual incidence in Australia of paediatric hospitalizations for empyema and pneumonia (viral and bacterial) before and after the introduction of PCV7 among children in the We compared the incidence of hospitalization for all pneumonias, as well as for bacterial and viral pneumonia separately and for empyema, in the pre-and post-vaccine periods. We estimated the expected number of hospitalizations in the post-vaccine period by multiplying the hospitalization incidence rate in the pre-vaccine period by the number of person-years in the postvaccine period. We also calculated incidence rate differences (IRD = incidence rate in pre-vaccine period minus incidence rate in post-vaccine period) and incidence rate ratios (IRR = incidence rate in post-vaccine period divided by incidence rate in pre-vaccine period) with their exact 95%
confidence intervals (CIs), assuming a Poisson distribution.
Results
Overall, 78 552 and 53 052 pneumonia-coded hospitalizations took place in the periods before and after the introduction of the PCV7, respectively. The incidence of hospitalizations was 22% lower in the post-vaccine period than in the pre-vaccine period (IRR: 0.78; 95% CI: 0.77-0.78) (Fig. 1 , Table 1 ). This reduction in hospitalization incidence was greatest among children whose age made them eligible for vaccination (i.e. < 1 year and 1 to 4 years in age) but was observed in all age groups. Most of the decrease in the incidence of hospitalizations was noted among children hospitalized for pneumonia with a bacteria-specific code (Table 1 ). In contrast, the incidence of hospitalizations coded as being for empyema was 35% higher (IRR: 1.35; 95% CI: 1.14-1.59) in the post-vaccine period than in the pre-vaccine period (Fig. 2, Table 1 ); the incidence of hospitalizations coded for viral pneumonia was 31% higher (IRR: 1.31; 95% CI: 1.27-1.35) (Table 1) . However, the absolute increase in the incidence of hospitalizations for empyema and for viral pneumonia (3 and 70 hospitalizations more per 10 6 person-years, respectively) was much smaller than the absolute decrease in the incidence of hospitalization for bacterial pneumonia (623 hospitalizations fewer per 10 6 person-years). On subgroup analysis, the increase in empyema was only significant among children aged 1 to 4 years, which was the age group with the largest number of hospitalizations. There was little evidence of an increase in empyema among children born
Discussion
Hospitalizations for childhood empyema in Australia appear to have increased after the introduction of the PCV7, despite a significant decrease in hospitalizations for pneumonia as a whole over the same period. The reduction in the incidence of hospitalizations for pneumonia was greatest among children whose age made them eligible for vaccination (i.e. < 1 year and 1-4 years in age), but more modest reductions were also observed among older children. Although the increase in the incidence of hospitalizations for empyema (which is present in fewer than 1% of pneumonia hospitalizations) was greatly outweighed by the reduction in the incidence of hospitalizations for pneumonia, empyema accounts for an important fraction of the cases of severe, complicated pneumonia. We assume that the IRDs we report here are primarily the result of vaccine-attributable changes in the epidemiology of childhood pneumonia in Australia, although they could also be reflecting other factors, including underlying secular trends. Our method is analogous to the method used in studies in England and Scotland on trends in childhood pneumonia and empyema. 18, 19 We based this analysis on publicly available hospitalization and population data. A limitation of the study is that we used hospital discharge data coded for the primary diagnosis.
Bacterial pneumonias in children are difficult to distinguish from viral pneumonias because bacterial culture has a low positive yield. Furthermore, as many as 33% of the children with pneumonia are infected by mixed pathogens. 20 Hence, the coding data may be inaccurate. To avoid this problem, we chose to compare the hospitalization rates for pneumonia as a whole rather than for bacteria-specific pneumonias. The reduction in hospitalizations for bacterial pneumonia was accompanied by a smaller absolute increase in pneumonias coded as viral (Table 1) . This might reflect changes in coding practices or perhaps improvements in molecular diagnostics and a greater availability of viral antigens over time. Pneumonias coded as viral decreased among infants. This was also seen in a field trial of conjugate vaccine that demonstrated a reduction in viral pneumonia, presumably because viral pneumonia in young children is often complicated by co-infection with pneumococcus. 21 Another limitation of our study is that we only included hospitalizations for which pneumonia and empyema were the primary diagnosis. Hence, our findings probably represent minimum estimates of disease incidence. Furthermore, we were unable to perform subgroup analysis by ethnic group and place of residence because these data are not publicly available.
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For convenience, we examined the period preceding and the period following the introduction of the PCV7. Since the vaccine was introduced in January 2005, we excluded from the analysis all data for the period from July 2004 to June 2005 (Table 1) . Nonetheless, the post-vaccine period included some children whose age would not have made them eligible for vaccination, and this could have resulted in an underestimation of vaccine's effect except in the youngest age group (< 1 year). In addition, targeted vaccination of indigenous children occurred during part of the prevaccine period. However, this probably affected our estimates only minimally since indigenous people account for only 3% of the Australian population. 22 Although the PCV7 has substantially reduced the rates of invasive pneumococcal disease, reports from around the world suggest that the incidence of empyema in children has increased following the introduction of the PCV7. 19A, 23 which are believed to be particularly virulent and more likely to invade the pleural cavity. 24, 25 The reported increase in serotypes 1, 3 and 19A among invasive isolates might explain the increase in empyema but not in pneumonia per se. [10] [11] [12] On the other hand, an increase in the incidence of empyema was observed in some studies before the introduction of the PCV7. 2, [26] [27] [28] This suggests that the observed association between the introduction of the PCV7 and the rise in empyema incidence may be coincidental.
Irrespective of its cause, the observed increase in empyema adds to health system costs. In a clinical study in the United Kingdom, we calculated that the cost per admission for a child with empyema was between 7600 and 11 700 United States dollars (US$). 29 A study in the United States yielded similar estimates. 30 Thus, the 35% increase in empyema admissions observed in Australia following the introduction of the PCV7 has brought an additional expenditure of US$ 126 160 to US$ 194 220 per year to the Australian health-care system. On the other hand, the reduction in pneumonia admissions has saved the health system US$ 3.8 million to US$ 6.1 million annually (based on United Kingdom cost analysis data for pneumonia admissions).
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. Although modest, the additional costs owing to the increase in cases of empyema among children would be reduced by the use of a vaccine with broader pneumococcal serotype coverage. Despite this, the large number of pneumococcal serotypes that have been identified makes it likely that other virulent pneumococcal strains will emerge. This underscores the need for on-going, enhanced molecular surveillance of invasive pneumococcal strains, including those that cause empyema in children. The results of such surveillance, which is already being practised in the United Kingdom, will directly affect future policy decisions regarding the adoption of newer vaccines as part of the national immunization schedule in Australia. Table 1 . Incidence rate differences (IRDs) and incidence rate ratios (IRRs) for paediatric hospitalizations for pneumonia and empyema before and after the introduction of the 7-valent pneumococcal conjugate vaccine, Australia
